The paper presents the main results of the clinical use of the drug "Immeran" in clinical practice in patients with the new coronavirus infection COVID-19, combined with gastric ulcer or duodenal ulcer. The patients received anticoagulants, antibacterial, antiulcer and antiviral therapy on an outpatient basis. Based on the results of an objective examination and a clinics, a diagnosis was made that corresponds to U07.1 - a new coronavirus infection COVID-19. The results allow us to note a positive trend in computed tomography of the chest organs (CT CO) - a decrease in the lung parenchyma percentage of damage and a rapid normalization of the patient's body temperature - within 2-3 days from the start of the drug "Immeran" injections. At the same time, the use of the drug "Immeran" was well tolerated, no undesirable side effects were observed.
"Immeran", polysaccharide, SARS-CoV-2, COVID-19, CT, pneumonia
1. Yueping Li, Zhiwei Xie et al. An exploratory randomized controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). April 15, 2020. medRxiv 2020.03.19.20038984. DOI:https://doi.org/10.1101/2020.03.19.20038984.
2. Magagnoli J., Narendran S. et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv preprint. DOI:https://doi.org/10.1101/2020.04.16.20065920. this version posted April 21, 2020.
3. Liu S., Lien C.Z., Selvaraj P., Wang T.T. Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection. bioRxiv 2020.04.29.067983. DOI:https://doi.org/10.1101/2020.04.29.067983.
4. Rezyume po doklinicheskomu izucheniyu lekarstvennogo sredstva «Immeran, rastvor dlya vnutrivennogo vvedeniya 0,5 mg/ml» @@Rezyume po doklinicheskomu izucheniyu lekarstvennogo sredstva «Immeran, rastvor dlya vnutrivennogo vvedeniya 0,5 mg/ml» (In Russ.)
5. Generalov E.A. Vliyanie polisaharidnogo preparata «Immeran» na techenie yazvennoy bolezni zheludka i dvenadcatiperstnoy kishki. Aktual'nye voprosy biologicheskoy fiziki i himii. BFFH-2019. @@Generalov E.A. Vliyanie polisaharidnogo preparata «Immeran» na techenie yazvennoj bolezni zheludka i dvenadcatiperstnoj kishki. Aktual'nye voprosy biologicheskoj fiziki i himii. BFFH-2019. (In Russ.)
6. Scherbakov P.L., Burian E.F., Vihrova T.V. i dr. Novye medicinskie tehnologii v terapii yazvennoy bolezni. Lechenie i profilaktika, 2011, vyp. 1, s. 22-25. @@Shcherbakov P.L., Burian E.F., Vihrova T.V. i dr. Novye medicinskie tekhnologii v terapii yazvennoj bolezni. Lechenie i profilaktika, 2011, vol. 1, pp. 22-25. (In Russ.)
7. Tanaka T., Narazaki M., Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb Perspect Biol., 2014, vol. 6 (10), p. a016295. DOI:https://doi.org/10.1101/cshperspect.a016295.
8. Luo Z., Lei H., Sun Y. et al. Orosomucoid, an acute response protein with multiple modulating activities. J. Physiol Biochem., 2015, vol. 71 (2), pp. 329-40. DOI:https://doi.org/10.1007/s13105-015-0389-9.
9. Wang F. et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. The Journal of Infectious Diseases, 2020. DOI:https://doi.org/10.1093/infdis/jiaa150.
